论文部分内容阅读
已有一些急性胰腺炎的病例报告称其与合并使用艾塞那肽、西格列汀,以及未使用这些药物的2型糖尿病相关。而艾塞那肽或西格列汀是否增加急性胰腺炎的风险目前仍未可知。美国学者从某大型医药索赔数据库(Medical and Pharmacy Claims Database)中选取786656例患者的资料进行了一项前瞻性队列研究。结果发现,各组胰腺炎的发病率分别为:非糖尿病对照组1.9/1000人年、糖尿病对照组5.6/1000人年、艾塞
Some cases of acute pancreatitis have been reported as associated with combined use of exenatide, sitagliptin, and type 2 diabetes without these drugs. Whether exenatide or sitagliptin increase the risk of acute pancreatitis is still unknown. American scholars conducted a prospective cohort study of 786,656 patients from a large Medical and Pharmacy Claims Database. The results showed that the incidence of pancreatitis in each group were: non-diabetic control group 1.9 / 1000 person-years, diabetic control group 5.6 / 1000 person-years,